BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 16417650)

  • 1. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
    Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
    Journe F; Chaboteaux C; Dumon JC; Leclercq G; Laurent G; Body JJ
    Br J Cancer; 2004 Nov; 91(9):1703-10. PubMed ID: 15477866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Lau KM; LaSpina M; Long J; Ho SM
    Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ICI 164384 and beta-interferon on the growth and steroid receptor profile of breast cancer cell lines.
    Coradini D; Biffi A; Pirronello E; Di Fronzo G
    Anticancer Res; 1995; 15(6B):2557-61. PubMed ID: 8669823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein.
    Pink JJ; Jiang SY; Fritsch M; Jordan VC
    Cancer Res; 1995 Jun; 55(12):2583-90. PubMed ID: 7780972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
    Barrón-González A; Castro Romero I
    Biochem Cell Biol; 2004 Apr; 82(2):335-42. PubMed ID: 15060629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation.
    Zhou-Li F; Albaladejo V; Joly-Pharaboz MO; Nicolas B; Andre J
    Endocrinology; 1992 Mar; 130(3):1145-52. PubMed ID: 1537281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
    Lazennec G; Katzenellenbogen BS
    Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
    Catherino WH; Wolf DM; Jordan VC
    Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
    Jain PT; Pento JT; Magarian RA
    Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
    Harnagea-Theophilus E; Gadd SL; Knight-Trent AH; DeGeorge GL; Miller MR
    Toxicol Appl Pharmacol; 1999 Mar; 155(3):273-9. PubMed ID: 10079213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.